Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Re: \"Noncoding RNAs Interplay in Ovarian Cancer Therapy and Drug Resistance\" by Liu et al.","authors":"Belma Gözde Özdemir","doi":"10.1089/cbr.2023.0167","DOIUrl":"10.1089/cbr.2023.0167","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"102"},"PeriodicalIF":3.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138801636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment of Reviewers 2023.","authors":"","doi":"10.1089/cbr.2023.29016.ack","DOIUrl":"10.1089/cbr.2023.29016.ack","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":"39 1","pages":"103"},"PeriodicalIF":3.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Role of [¹⁸F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study.","authors":"Luca Filippi, Ilaria Proietti, Vincenzo Petrozza, Concetta Potenza, Oreste Bagni, Orazio Schillaci","doi":"10.1089/cbr.2023.0110","DOIUrl":"10.1089/cbr.2023.0110","url":null,"abstract":"<p><p><b><i>Background:</i></b> Baseline 2-deoxy-2[¹⁸F]fluoro-d-glucose ([¹⁸F]FDG) positron emission tomography (PET)-derived parameters and 12-week metabolic response were investigated as prognostic factors in advanced cutaneous squamous cell carcinoma (cSCC) submitted to cemiplimab immunotherapy. <b><i>Materials and Methods:</i></b> Clinical records of 25 cSCC patients receiving cemiplimab, submitted to [¹⁸F]FDG positron emission tomography/computed tomography (PET/CT) at baseline and after ∼12 weeks, were retrospectively reviewed. The Kaplan-Meier (KM) method was applied to analyze differences in event-free survival (EFS), and Cox regression analysis was employed to identify the prognostic factors. <b><i>Results:</i></b> At the 12-week PET/CT evaluation, 16 patients (64%) were classified as responders (complete or partial response) and 9 (36%) as nonresponders (\"unconfirmed progressive metabolic disease\") according to immune PET Response Criteria in Solid Tumors (iPERCIST). By KM analysis, baseline metabolic tumor volume (MTV) and total lesion glycolysis (TLG) significantly correlated with the EFS (<i>p</i> < 0.05). Furthermore, the KM analysis showed that the lack of metabolic response at 12 weeks was associated with meaningfully shorter EFS (7.2 ± 1 months in nonresponders vs. 20.3 ± 2.3 months in responders). In Cox multivariate analysis, metabolic response at 12 weeks remained the only predictor of the EFS (<i>p</i> < 0.05). <b><i>Conclusions:</i></b> Baseline tumor load (i.e., MTV and TLG) and metabolic response at 12 weeks may have a prognostic impact in cSCC patients treated with cemiplimab.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"46-54"},"PeriodicalIF":3.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54232380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of ¹⁷⁷Lu-Labeled Pertuzumab F(ab')₂ Fragments for HER2-Positive Cancer Targeting: A Comparative <i>In Vitro</i> and <i>In Vivo</i> Study.","authors":"Rohit Sharma, Archana Mukherjee, Anuj Kumar, Haladhar Dev Sarma","doi":"10.1089/cbr.2023.0108","DOIUrl":"10.1089/cbr.2023.0108","url":null,"abstract":"<p><p><b><i>Background:</i></b> Radiolabeled antibody fragments present a promising opportunity as theranostic agents, offering distinct advantages over whole antibodies. In this study, the authors investigate the potential of [¹⁷⁷Lu]Lu-DTPA-F(ab')₂-pertuzumab as a theranostic agent for precise targeting of human epidermal growth factor receptor 2 (HER2)-positive cancers. Additionally, the authors aim to quantitatively assess the binding synergism in the presence of cold trastuzumab. <b><i>Materials and Methods:</i></b> F(ab')₂-pertuzumab was prepared by pepsin digestion and conjugated with a bifunctional chelator. The immunoconjugate was radiolabeled with ¹⁷⁷Lu and characterized by chromatography techniques. Binding parameters (affinity, specificity, and immunoreactivity) and cellular binding enhancement studies were evaluated in HER2-overexpressing and triple-negative cell lines. The <i>in vivo</i> enhancement in tumor uptake of the radiolabeled immunoformulation was assessed in severe combined immunodeficient (SCID) mice bearing tumors, both in the presence and absence of unlabeled trastuzumab. <b><i>Results:</i></b> The formulation of [¹⁷⁷Lu]Lu-DTPA-F(ab')₂-pertuzumab could be prepared in high yields and with consistent radiochemical purity, ensuring reproducibility. Comprehensive <i>in vitro</i> and <i>in vivo</i> evaluation studies confirmed high specificity and immunoreactivity of the formulation toward HER2 receptors. Binding synergism of radiolabeled pertuzumab fragments in the presence of trastuzumab to HER2 receptors was observed. <b><i>Conclusions:</i></b> The radioformulation of [¹⁷⁷Lu]Lu-DTPA-F(ab')₂-pertuzumab holds great promise as a targeted approach for addressing HER2-positive cancers. A potentially effective strategy to amplify therapeutic efficacy involves dual epitope targeting by combining radiolabeled pertuzumab with cold trastuzumab.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":"39 1","pages":"64-74"},"PeriodicalIF":3.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery.","authors":"Aman Mourya, Navnit Prajapati","doi":"10.1089/cbr.2023.0031","DOIUrl":"10.1089/cbr.2023.0031","url":null,"abstract":"<p><p>Cancer chemotherapy has been shifted from conventional cytotoxic drug therapy to selective and target-specific therapy after the findings about DNA changes and proteins that are responsible for cancer. A large number of newer drugs were discovered as targeted therapy for particular types of neoplastic disease. The initial discovery includes the development of the first in the category, imatinib, a Bcr-Abl tyrosine kinase inhibitor (TKI) for the treatment of chronic myelocytic leukemia in 2001. But the joy did not last for long as the drug developed a point mutation within the ABL1 kinase domain of BCR-ABL1, which subsequently led to the discovery of many other TKIs. Resistance was observed for newer TKIs a few years after their launching, but the use of TKIs in life-threatening cancer therapy is considered as far better compared with the risks of disease because of its target specificity and hence less toxicity. In search of a better anticancer agent, the physiochemical properties of the lead molecule have been modified for its efficacy toward disease and delay in the development of resistance. Deuteration in the drug molecule is one of such modifications that alter the pharmacokinetic properties, generally its metabolism, as compared with its pharmacodynamic effects. Precision deuteration in many anticancer drugs has been carried out to search for better drugs for cancer. In this review, the majority of anticancer drugs and molecules for which deuteration was applied to get better anticancer molecules were discussed. This review will provide a complete guide about the benefits of deuteration in cancer chemotherapy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"1-18"},"PeriodicalIF":3.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10016144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<b><i>NUCKS1</i></b> Acts as a Promising Novel Biomarker for the Prognosis of Patients with Hepatocellular Carcinoma.","authors":"Xianfeng Zhang, Xianjun Zhang, Xinguo Li, Hongbing Bao, Guang Li, Ning Li, Hengli Li, Jian Dou","doi":"10.1089/cbr.2020.4226","DOIUrl":"10.1089/cbr.2020.4226","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Nuclear casein kinase and cyclin-dependent kinase substrate 1 (<i>NUCKS1</i>) is highly expressed in some tumors, including hepatocellular carcinoma (HCC). However, its clinical significance in HCC prognosis is still unclear. The aim of this study was to explore the expression and prognostic value of <i>NUCKS1</i> in HCC. <b><i>Materials and Methods:</i></b> Quantitative real-time polymerase chain reaction was used to detect relative expression of <i>NUCKS1</i> mRNA in HCC tissues and corresponding adjacent normal tissues. The relationship between <i>NUCKS1</i> expression and clinical characteristics of patients was analyzed by χ² test. Kaplan-Meier method and Cox regression analysis were applied to estimate prognostic value of <i>NUCKS1</i> in HCC. <b><i>Results:</i></b> Compared with normal ones, the expression of <i>NUCKS1</i> mRNA was significantly upregulated in HCC tissues (<i>p</i> < 0.001). Besides, <i>NUCKS1</i> expression was closely associated with tumor differentiation, tumor node metastasis stage, vascular invasion, and metastasis (<i>p</i> < 0.05). Kaplan-Meier analysis revealed that overall survival was obviously longer in HCC patients with low expression of <i>NUCKS1</i> than those with high <i>NUCKS1</i> expression (log rank test, <i>p</i> = 0.001). <i>NUCKS1</i> might be an independent prognostic factor for HCC patients (HR = 1.905, 95% CI = 1.106-3.283, <i>p</i> = 0.020). <b><i>Conclusions:</i></b> <i>NUCKS1</i> may be correlated with the progression of HCC and serve as a potential predictive factor for the prognosis of this disease.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"720-725"},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25381343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circ_0058058 Knockdown Inhibits Acute Myeloid Leukemia Progression by Sponging miR-4319 to Regulate <i>EIF5A2</i> Expression.","authors":"Ting Zhang, Ying Zhou, Jun Guan, Hui Cheng","doi":"10.1089/cbr.2020.4170","DOIUrl":"10.1089/cbr.2020.4170","url":null,"abstract":"<p><p><b><i>Background:</i></b> Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Circular RNAs (circRNAs) participate in the deterioration of many hominine cancers, including AML. In this study, the authors investigated the role and potential mechanism of circ_0058058 in AML progression. <b><i>Methods:</i></b> The expression of circ_0058058, microRNA-4319 (miR-4319), and eukaryotic initiation factor 5A2 (<i>EIF5A2</i>) was determined by quantitative real-time polymerase chain reaction. Cell proliferation, apoptosis, migration, and invasion were evaluated by cell counting kit-8 (CCK-8), cell colony formation, flow cytometry, and transwell assay, respectively. Levels of the relative proteins were detected by Western blot. The connection among circ_0058058, miR-4319, and <i>EIF5A2</i> was verified by dual-luciferase reporter assay. <b><i>Results:</i></b> Circ_0058058 and <i>EIF5A2</i> were enhanced, whereas miR-4319 was declined in AML. Circ_0058058 knockdown inhibited cell proliferation, migration, and invasion, and facilitated cell apoptosis by targeting miR-4319 in AML cells. Moreover, as a target of miR-4319, <i>EIF5A2</i> overexpression overturned the inhibitory effects of miR-4319 upregulation on AML progression. Besides, circ_0058058 sponged miR-4319 to upregulate <i>EIF5A2</i> expression in AML cells. <b><i>Conclusion:</i></b> Circ_0058058 knockdown inhibited cell proliferation, migration, and invasion, but accelerated cell apoptosis by reducing <i>EIF5A2</i> expression by targeting miR-4319, suggesting that circ_0058058 could be a therapeutic target for the treatment of AML.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"738-748"},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38839194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of ^99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging.","authors":"Ghazal Norouzi, Sara Nikdel, Elahe Pirayesh, Yazdan Salimi, Mahasti Amoui, Hamidreza Haghighatkhah, Mohammad Ali Ghodsi Rad, Elmira Javanijouni, Sepideh Khoshbakht","doi":"10.1089/cbr.2022.0062","DOIUrl":"10.1089/cbr.2022.0062","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> Nonalcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disease worldwide, with functional impairment of the mitochondria occurring from early stages. Technetium-99m methoxy-isobutyl-isonitrile (^99mTc-MIBI) is a lipophilic agent trapped in the mitochondria. This study aims to evaluate the utility of ^99mTc-MIBI heart/liver uptake ratio in screening for NAFLD during myocardial perfusion imaging (MPI). <b><i>Methods:</i></b> Seventy eligible patients underwent a 2-d rest/stress ^99mTc-MIBI scan with a 2-min planar image acquired in rest phase, at 30, 60, and 120 min postradiotracer administration. Heart/liver uptake ratio was calculated by placing identical regions of interest on the heart and liver dome. All patients underwent liver ultrasound and were allocated into groups A, having NAFLD; and B, healthy individuals without NAFLD. <b><i>Results:</i></b> Mean count per pixel heart/liver ratios gradually increased over time in either group; nonetheless the values were significantly higher in group A, regardless of acquisition timing; with the <i>p</i>-value equal to 0.007, 0.014, and 0.010 at 30, 60, and 120 min, respectively. <b><i>Conclusion:</i></b> Determining ^99mTc-MIBI heart/liver uptake ratio during rest phase in patients undergoing MPI may be a useful, noninvasive screening method for NAFLD; with no additional cost, radiation burden, or adverse effects in these patients. Trial registration number: IR.SBMU.MSP.REC.1398.308.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"663-669"},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10448509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues.","authors":"Wang-Yang Ye, Hui-Ping Lu, Jian-Di Li, Gang Chen, Rong-Quan He, Hua-Yu Wu, Xian-Guo Zhou, Min-Hua Rong, Li-Hua Yang, Wei-Ying He, Qiu-Yu Pang, Shang-Ling Pan, Yu-Yan Pang, Yi-Wu Dang","doi":"10.1089/cbr.2020.4342","DOIUrl":"10.1089/cbr.2020.4342","url":null,"abstract":"<p><p><b><i>Background:</i></b> To date, the clinical management of advanced hepatocellular carcinoma (HCC) patients remains challenging and the mechanisms of E2F transcription factor 1 (E2F1) underlying HCC are obscure. <b><i>Materials and Methods:</i></b> Our study integrated datasets mined from several public databases to comprehensively understand the deregulated expression status of E2F1. Tissue microarrays and immunohistochemistry staining was used to validate E2F1 expression level. The prognostic value of E2F1 was assessed. In-depth subgroup analyses were implemented to compare the differentially expressed levels of E2F1 in HCC patients with various tumor stages. Functional enrichments were used to address the predominant targets of E2F1 and shedding light on their potential roles in HCC. <b><i>Results:</i></b> We confirmed the elevated expression of E2F1 in HCC. Subgroup analyses indicated that elevated E2F1 level was independent of various stages in HCC. E2F1 possessed moderate discriminatory capability in differentiating HCC patients from non-HCC controls. Elevated E2F1 correlated with Asian race, tumor classification, neoplasm histologic grade, eastern cancer oncology group, and plasma AFP levels. Furthermore, high E2F1 correlated with poor survival condition and pooled HR signified E2F1 as a risk factor for HCC. Enrichment analysis of differentially expressed genes, coexpressed genes, and putative targets of E2F1 emphasized the importance of cell cycle pathway, where <i>CCNE1</i> and <i>CCNA2</i> served as hub genes. <b><i>Conclusions:</i></b> We confirmed the upregulation of E2F1 and explored the prognostic value of E2F1 in HCC patients. Two putative targeted genes (<i>CCNE1</i> and <i>CCNA2</i>) of E2F1 were identified for their potential roles in regulating cell cycle and promote antiapoptotic activity in HCC patients.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"684-707"},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39493984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-424 Acts as a Novel Biomarker in the Diagnosis of Patients with Hepatocellular Carcinoma.","authors":"Chao Yang, Peng Du, Wei Lu","doi":"10.1089/cbr.2020.4141","DOIUrl":"10.1089/cbr.2020.4141","url":null,"abstract":"<p><p><b><i>Objective:</i></b> MicroRNA-424 (MiR-424) is proved to be a tumor suppressor against many malignancies, including hepatocellular carcinoma (HCC). Nevertheless, its role in diagnosing HCC remained poorly understood. The authors' research investigated diagnostic value of serum miR-424 in HCC. <b><i>Materials and Methods:</i></b> Relative expression levels of serum miR-424 in HCC patients and healthy individuals were measured via quantitative real-time polymerase chain reaction. χ² test was applied to analyze the correlation between miR-424 expression and clinical features of HCC cases. Diagnostic value was estimated via plotting a receiver operating characteristic (ROC) curve. <b><i>Results:</i></b> Serum miR-424 expression was obviously downregulated in HCC cases in comparison to healthy persons (<i>p</i> < 0.001). miR-424 expression presented strong correlation with tumor node metastasis stage (<i>p</i> = 0.022), Barcelona Clinic Liver Cancer stage (<i>p</i> < 0.001), metastasis (<i>p</i> = 0.037), and vein invasion (<i>p</i> = 0.033). ROC curve analysis manifested an area under the curve of 0.768 with a sensitivity of 75.0% and a specificity of 72.4%, suggesting that serum miR-424 had high diagnostic value in HCC patients. <b><i>Conclusions:</i></b> The data suggest that serum miR-424 may represent a biomarker in early detection of HCC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"670-673"},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39205466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}